Piramal Pharma Ltd (PPL) Chairperson Nandini Piramal said that the company intends to invest around Rs 1,000 crore over the next 18 months towards consolidating, and growth through brownfield expansions.

“For the second half of the fiscal year, the company plans to deploy around ₹330 crore, focusing on revenue gain, operational excellence, and making the added brownfield capacities more productive," Piramal added.

She further said,"“And then probably on similar lines, ₹660 crore for the full fiscal year. Our capex (capital expenditure) is not only a mix of maintenance, but also brownfield expansions, as and when the right opportunities appear. And we should see significant margin improvement overall."

The Mumbai-based pharma company reported a 14% year-on-year (YoY) rise in its revenue from operations in the first half of the current fiscal year.

This growth spans across its three operational verticals - contract development and manufacturing organisation (CDMO), complex hospital generics (CHG), and India consumer healthcare (ICH), all of which have reported double-digit growth.